Tempest Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
28/03/2025 12:00
Tempest Therapeutics Inc TPST.OQ reported a quarterly adjusted loss of 31 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -38 cents. The mean expectation of five analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -30 cents to -19 cents per share. Reported revenue was zero; analysts expected zero. Tempest Therapeutics Inc's reported EPS for the quarter was a loss of 31 cents. The company reported a quarterly loss of $13.81 million. Tempest Therapeutics Inc shares had risen by 0.7% this quarter. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Tempest Therapeutics Inc is $8.50 This summary was machine generated from LSEG data March 28 at 12:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.25 | -0.31 | Missed |
| Sep. 30 2024 | -0.36 | -0.41 | Missed |
| Jun. 30 2024 | -0.40 | -0.42 | Missed |
| Mar. 31 2024 | -0.37 | -0.36 | Beat |
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T